- Home
- ESLA
as 11-22-2024 4:00pm EST
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 41.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 16.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $3.23 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Estrella Immunopharma Inc. News
ESLA Breaking Stock News: Dive into ESLA Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider
Business Wire
2 months ago
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
Business Wire
3 months ago
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
Exec Edge
10 months ago
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases
Simply Wall St.
10 months ago
Investors Met With Slowing Returns on Capital At PermRock Royalty Trust (NYSE:PRT)
InvestorPlace
10 months ago
3 Penny Stocks AI Predicts Will Skyrocket 10,000%
Zacks
10 months ago
Evolution (EPM) Expands Asset Base, Signs $43.5M Contract
InvestorPlace
10 months ago
7 A-Rated Semiconductor Stocks to Buy in January
Compare ESLA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESLA Estrella Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.